Stock Movers

On This episode of Stock Movers:
- BP Plc agreed to sell a majority stake in its Castrol lubricants division to US investment firm Stonepeak Partners to raise about $6 billion.
- Sanofi agreed to buy Dynavax Technologies Corp. for about $2.2 billion, as the French drugmaker tries to expand a vaccines business currently anchored by its flu shot franchise.
- Fresnillo and other european mining stocks may be active on Wednesday as gold rises above $4,500 an ounce for the first time on escalating tensions in Venezuela and expectations for more US interest rate cuts. Silver, platinum and copper also hit records

See omnystudio.com/listener for privacy information.

On this episode of Stock Movers:
- Novo Nordisk (NVO) shares rallied in trading today following the drugmaker getting US approval to sell a pill version of its blockbuster obesity shot Wegovy. Novo will start selling the pill in the US in early January, the company said in a statement Monday. It is approved to help people lose weight or maintain previous weight loss over the long term. The pill is crucial for Novo’s strategy to take on Eli Lilly, which has said its own oral obesity drug could be approved by March. That would give Novo a head start of just a few months.
- ServiceNow (NOW) has reached a deal to buy the cybersecurity startup Armis in a deal valued at $7.75 billion, representing its largest acquisition to date. The Santa Clara, California-based enterprise tech company will pay in cash for San Francisco-based Armis, according to a statement Tuesday that confirmed an earlier Bloomberg News report. ServiceNow, which provides software that helps companies organize and automate their personnel and information technology operations, has become a dominant platform for enterprise workflow. In March, ServiceNow struck an agreement to buy the artificial intelligence firm Moveworks Inc. for $2.85 billion as part of its push into AI tools that can complete tasks without human supervision. Shares of the startup fell during trading on Tuesday.
- Sable (SOC) shares rose as much as 30% after the company said that the US Department of Transportation, Pipeline and Hazardous Materials Safety Administration approved the firm’s Las Flores pipeline restart plan.

See omnystudio.com/listener for privacy information.

On this episode of Stock Movers:
- Novo Nordisk (NVO) won approval to sell a pill version of its blockbuster obesity shot Wegovy in the US, a crucial step in its effort to defend its market share from rival Eli Lilly. The shares soared by as much as 11% in Copenhagen, the biggest intraday gain since August. Novo has fallen by almost half this year amid concern about the Danish drugmaker’s ability to compete in the obesity market it pioneered. Shares continued to rally in New York trading on Tuesday.
- Johnson & Johnson (JNJ) was ordered to pay about $1.56 billion to a Maryland woman who blamed the company’s talc-based baby powder for causing her asbestos-linked cancer, the largest such verdict for an individual in 15 years of litigation. The verdict comes as J&J has been pummeled by a recent spate of baby powder verdicts after it failed this year to use bankruptcy court to force a settlement of more than 70,000 lawsuits accusing the company of hiding the product’s cancer risks. Shares of the company fell in trading on Tuesday.
- ServiceNow (NOW) has reached a deal to buy the cybersecurity startup Armis in a deal valued at $7.75 billion, representing its largest acquisition to date. Shares in ServiceNow fell about 1.3% in early trading before markets opened in New York. They closed up around 0.9% on Monday, giving the company a market valuation of about $163 billion.

See omnystudio.com/listener for privacy information.

On this episode of Stock Movers:
- Novo Nordisk (NOVOB) won approval to sell a pill version of its obesity shot Wegovy in the US, to help people lose weight or maintain previous weight loss over the long term. The company will start selling the pill in the US in early January, and it is approved based on the results of the Oasis 4 trial, which found people taking the pill lost about 13.6% of their body weight over 64 weeks.
- Johnson & Johnson (JNJ) was ordered to pay about $1.56 billion to a Maryland woman who blamed the company's talc-based baby powder for causing her asbestos-linked cancer.
- ServiceNow Inc. has reached a deal to buy the cybersecurity startup Armis in a deal valued at $7.75 billion, representing its largest acquisition to date. Shares have fallen over 4% on the news.

See omnystudio.com/listener for privacy information.

On this episode of Stock Movers:
- Novo Nordisk (NOVOB) won approval to sell a pill version of its blockbuster obesity shot Wegovy in the US, a crucial step in its effort to defend its market share from rival Eli Lilly (LLY). The shares soared by as much as 11% in Copenhagen, the biggest intraday gain since August. Novo has fallen by almost half this year amid concern about the Danish drugmaker’s ability to compete in the obesity market it pioneered.
- Copper hit a fresh all-time high above $12,000 a ton due to severe mine outages and trade dislocations linked to US President Donald Trump’s tariff agenda. Shares of Albemarle climbed as a result.
- The US Navy announced plans to build a new class of warship, the FF(X), as part of President Donald Trump's "Golden Fleet" bid to revive US shipbuilding. That caused shares of Huntington Ingalls Industries Inc. to rise.

See omnystudio.com/listener for privacy information.

On this episode of Stock Movers:
- Shares of Novo Nordisk (NVO) soared in premarket trading after the company won approval to sell a pill version of its blockbuster obesity shot Wegovy in the US, a crucial step in its effort to defend its market share from rival Eli Lilly & Co. Novo will start selling the pill in the US in early January, the company said in a statement Monday. It is approved to help people lose weight or maintain previous weight loss over the long term.
- Shares of naval shipmaker Huntington Ingalls (HII) rallied ahead of the US market open after President Trump announced the Navy will build a new “Trump-class” battleship as part of the White House push to modernize a fleet that’s been hobbled by years of cost overruns and delays.
- Shares of Copenhagen-listed Orsted (ORSTED DC) declined after the company said it’s considering “all options” including legal action as it weighs how to respond to a US decision to suspend leases for five offshore wind farms, according to a statement late Monday. Orsted said its farms — Revolution Wind and Sunrise Wind — had secured all the required federal and state permits, including consulting “closely and directly” with US authorities to “to evaluate and address potential impacts to national security and defense capabilities.

See omnystudio.com/listener for privacy information.

On this episode of Stock Movers:

- Shares of Novo Nordisk (NVO) soared in premarket trading after the company won approval to sell a pill version of its blockbuster obesity shot Wegovy in the US, a crucial step in its effort to defend its market share from rival Eli Lilly & Co. Novo will start selling the pill in the US in early January, the company said in a statement Monday. It is approved to help people lose weight or maintain previous weight loss over the long term.

- Shares of naval shipmaker Huntington Ingalls (HII) rallied ahead of the US market open after President Trump announced the Navy will build a new “Trump-class” battleship as part of the White House push to modernize a fleet that’s been hobbled by years of cost overruns and delays.

- Shares of Warner Bros. Discovery (WBD) edged higher in the early session as Larry Ellison is throwing his personal fortune behind Paramount Skydance Corp.’s bid for WBD, aiming to give his son’s company an advantage in a fiercely contested takeover battle with Netflix Inc.

See omnystudio.com/listener for privacy information.

On This episode of Stock Movers:

- Novo Nordisk won approval to sell a pill version of its blockbuster obesity shot Wegovy in the US, a crucial step in its effort to defend its market share from rival Eli Lilly.

- Ryanair was fined more than €255 million ($300 million) by Italy’s antitrust watchdog for allegedly using an “abusive strategy” to thwart third-party travel agencies.

- Cevian Capital raises its total holding in Akzo Nobel NV to 10.15% from ~5%, according to a filing with the Dutch financial authority AFM.

See omnystudio.com/listener for privacy information.

On This episode of Stock Movers:

- Novo Nordisk won approval to sell a pill version of its blockbuster obesity shot Wegovy in the US, a crucial step in its effort to defend its market share from rival Eli Lilly.

- Orsted said it’s considering “all options” including legal action as it weighs how to respond to a US decision to suspend leases for five offshore wind farms, according to a statement late Monday.

- Pets at Home Group named James Bailey, the former managing director of upmarket grocer Waitrose, as its new chief executive officer to lead a reboot of the struggling pet care company. 

See omnystudio.com/listener for privacy information.

On this episode of Stock Movers:
- Warner Bros. Discovery (WBD) shares rallied in trading today after word that Larry Ellison is throwing his personal fortune behind Paramount Skydance Corp.’s bid for it, aiming to give his son’s company an advantage in a fiercely contested takeover battle with Netflix. Paramount has been aggressively pursuing Warner Bros. for months and Ellison was taken by surprise when the board agreed to a deal with Netflix for $82.7 billion for the streaming and studio assets. The strength of the financing for each bid has emerged as a decisive issue in the takeover battle, which unleashed two massive debt-fueled offers that rank among the largest in the past decade. Paramount took its offer of $30 a share, or $108.4 billion including debt, for the entire company directly to shareholders. Warner Bros. shares gained 3.4% in New York afternoon trading, and changed hands during the session for as much as $28.98. Paramount rose as much as 8.1% while Netflix dropped about 1%.
- First Solar (FSLR) rose as much as 7.1%, touching the highest intraday since June 2024, after news Alphabet will buy clean-energy developer Intersect Power in one of the company’s biggest deals aimed at boosting its AI-related data-center footprint. The stock was the top S&P 500 gainer with less than 10 minutes to the close. Other solar names with gains in Monday trading included: Canadian Solar up as much as 15%; Array Technologies rises as much as 10%; Nextpower +7.7%.
- Clearwater Analysts (CWAN) shares are up 8.5% on Monday, after a group of private equity firms agreed to buy the investment and accounting software company in a deal valuing it at $8.4 billion. Analysts said the deal price was lower than expected.

See omnystudio.com/listener for privacy information.